QT interval prolongation as a biomarker for torsades de pointes and sudden death in drug development |
| |
Authors: | Sides Gregory D |
| |
Affiliation: | Eli Lilly and Company, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46077, USA. gsides@lilly.com |
| |
Abstract: | Prolongation of the QT interval on the surface 12-lead electrocardiogram is widely accepted as a biomarker for the potential of a drug to produce torsades de pointes and/or sudden death. Detection of drug-induced prolongation of the QT interval in animals and man is frequently confounded by extrinsic and intrinsic factors that limit the ability to detect a true drug effect. In particular drugs that increase heart rate show an apparent increase in QT interval that confounds assessment of a true drug effect on cardiac ventricular repolarization. The basis for the use of the QT interval as a biomarker will be examined. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|